论文部分内容阅读
应用地高辛精标记C—myc和P~(53)基因探针原位杂交技术检测18例子宫肌瘤,48例交界性子宫平滑肌瘤和6例子宫平滑肌肉瘤中C—myc和P~(53)的定位及表达,探讨肿瘤基因与子宫平滑肌肿瘤的发生和发展有无相关性,以及交界性子宫平滑肌瘤与子宫肌瘤和平滑肌肉瘤间的内在联系。结果显示C—myc和P~(53)的表达产物均定位于细胞核中,在三型肿瘤中C—myc的表达率分别为5.6％、33.3％、50％;P~(53)的表达率分别为11.1％、39.8％、66.7％(P<0.05)。在肿瘤中的表达强度与细胞增殖程度成正比。推测C—myc和P~(53)突变及过量表达可能是子宫平滑肌肿瘤发生和发展的一个因素,交界性子宫平滑肌瘤可能为平滑肌肉瘤的前驱病变,具有特殊的生物学行为,经手术治疗,预后良好。
In this study, 18 cases of uterine fibroids, 48 cases of borderline uterine leiomyoma and 6 cases of uterine leiomyosarcoma were examined by in situ hybridization with digoxin marker C-myc and p53 gene probe. C-myc and P ~ (53) localization and expression to explore the tumor gene and uterine smooth muscle tumor occurrence and development of relevance, as well as the borderline uterine leiomyomas and uterine fibroids and leiomyosarcoma between the intrinsic link. The results showed that the expression products of C-myc and P53 were located in the nucleus. The expression rates of C-myc were 5.6%, 33.3% and 50% Respectively, 11.1%, 39.8%, 66.7% (P <0.05). The intensity of expression in the tumor is proportional to the degree of cell proliferation. It is speculated that the mutation and overexpression of C-myc and P53 may be one of the factors for the occurrence and development of uterine smooth muscle tumors. The borderline uterine leiomyomas may be the precursor lesions of leiomyosarcoma and have special biological behavior after surgery The prognosis is good.